Table 2.
Baseline demographic and clinical characteristics
| Characteristic, n (%) | N = 28 |
|---|---|
| Sex | |
| Male | 7 (25) |
| Female | 21 (75) |
| Age in years, median (range) | 62.5 (38‐81) |
| Histological type | |
| Adenocarcinoma | 24 (86) |
| Squamous‐cell carcinoma | 2 (7) |
| Large‐cell carcinoma | 1 (4) |
| Missing data | 1 (4) |
| Smoking status | |
| Never | 18 (64) |
| Current | 1 (4) |
| Former | 9 (32) |
| No. prior EGFR‐TKI at baseline, median (range) | 2.0 (1‐6) |
| EGFR mutation type by local cytology sample testing T790Ma | 28 (100) |
| Exon 19 deletion | 10 (36) |
| L858R | 8 (29) |
| EGFRm subtype unspecified | 1 (4) |
| Sensitizing mutation status unavailable | 9 (32) |
| WHO performance status | |
| 0 | 7 (25) |
| 1 | 21 (75) |
EGFR‐TKI, epidermal growth factor receptor‐tyrosine kinase inhibitor; EGFRm, EGFR‐TKI‐sensitizing mutation; WHO, World Health Organization.
a
Two patients had tissue samples available, enabling confirmation of T790M‐positive status by central cobas® test in both patients.